Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13900MR)

This product GTTS-WQ13900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13900MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14407MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ7272MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ7240MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ8043MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ1663MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ8721MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ14398MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ8532MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5A8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW